The putative impact on cancer hallmarks, through AT1 receptor blockade or activation of the ACE2/Ang-(1–7)/Mas receptor axis, has been linked to reduced tumor growth and vascularization in lung cancer, thus fostering the need for clinical studies. This evidence concerns the gene AGTR1 and lung cancer.